Intracranial Hemorrhage The Culprit In Merck's Vorapaxar Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck &Co. remains unsure about regulatory filing plans for the compound, while still waiting to see clinical trial data.